Last reviewed · How we verify

Iopamidol 300 (Contrast) — Competitive Intelligence Brief

Iopamidol 300 (Contrast) (Iopamidol 300 (Contrast)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-ionic iodinated contrast agent. Area: Diagnostic Imaging.

marketed Non-ionic iodinated contrast agent Diagnostic Imaging Small molecule Live · refreshed every 30 min

Target snapshot

Iopamidol 300 (Contrast) (Iopamidol 300 (Contrast)) — University of Michigan. Iopamidol is a non-ionic iodinated contrast agent that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Iopamidol 300 (Contrast) TARGET Iopamidol 300 (Contrast) University of Michigan marketed Non-ionic iodinated contrast agent
contrast agent (iopromide) contrast agent (iopromide) Seoul National University Bundang Hospital marketed Non-ionic iodinated contrast agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-ionic iodinated contrast agent class)

  1. Seoul National University Bundang Hospital · 1 drug in this class
  2. University of Michigan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Iopamidol 300 (Contrast) — Competitive Intelligence Brief. https://druglandscape.com/ci/iopamidol-300-contrast. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: